S&P Futures
3,980.75 +2.75 (+0.07%) Dow Futures
32,339.00 +20.00 (+0.06%) Nasdaq Futures
12,856.75 +2.75 (+0.02%) Russell 2000 Futures
1,738.50 +6.00 (+0.35%) Crude Oil
69.75 -0.21 (-0.30%) Gold
1,995.20 -0.70 (-0.04%)
Intellia Therapeutics, Inc. (NTLA)
After hours:
- Zacks
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.
- GlobeNewswire
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is an in vivo CRISPR-based investigational therapy designed t
- Motley Fool
3 Beaten-Down Stocks That Could Soar This Year
Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Exelixis (NASDAQ: EXEL), and Intellia Therapeutics (NASDAQ: NTLA). Prosper Junior Bakiny (CRISPR Therapeutics): Unprofitable clinical-stage biotech companies got hammered last year. Gene-editing specialist CRISPR Therapeutics fits that description to a T, so it got dragged down along with the broader market.
